32: Why Pharmaceutical Companies Face an Existential M&A Crisis

episode

Deal of the Week not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Planning Commission Meeting - Sep 17, 2026 1h 11m · 17 Sep 2026 · Leesburg Planning Commission

Heritage Commission - Sep 14, 2026 1h 57m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Historic District Review Committee - Sep 14, 2026 1h 36m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded29 Jun 2016

Publisheromnycontent.com ↗

Handlerec:15050800

Show notes

Sanofi and Boehringer Ingelheim agreed to a $25 billion dollar trade of big business units this week, the conclusion of a deal that first surfaced in December. Asset swaps, while complicated, could be an increasingly popular maneuver among pharmaceutical companies, Bloomberg M&A reporter Ed Hammond tells host and colleague Alex Sherman. That's partially because the biggest takeovers in the industry can't seem to get done. Hammond explains why they've failed and what pharma deals might actually get done in the second half of 2016.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in